As an agonist of TGR5, HDCA may play a role in modulating metabolism and energy expenditure, particularly showing potential therapeutic value in the treatment of metabolic disorders, such as obesity, diabetes, dyslipidemia, atherosclerosis, NAFLD, and neurological conditions (55). Here, GPBAR1 is linked to metabolic disease.